Non-invasive visible light imaging in drug discovery and development: A view from an industrial perspective

2004 ◽  
Author(s):  
Peter Lassota
Keyword(s):  
Drug Discovery ◽  
Visible Light ◽  
Drug Discovery And Development ◽  
Non Invasive ◽  
Visible Light Imaging

scholarly journals Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration

2018 ◽  
Vol 243 (13) ◽  
pp. 1037-1045 ◽  
Author(s):  
Abigail L Walker ◽  
Syed Z Imam ◽  
Ruth A Roberts
Keyword(s):  
Multiple Sclerosis ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Discovery ◽  
Small Molecule ◽  
Treatment Options ◽  
New Drugs ◽  
Drug Discovery And Development ◽  
Non Invasive ◽  
Small Molecule Drug

The discovery and development of new drugs are vital if we are to improve and expand treatment options available to improve outcomes for patients. Overall, therapeutic strategies fall into two broad categories: small molecules and biologics, although more recently there has been a growth in novel platforms such as miRNAs and oligonucleotides. On average, the development of a small molecule drug takes around 12 years and costs around $50m. Despite this huge investment of time and money, attrition remains a major challenge and very few molecules actually make it through to the market. Here, we look at reasons for attrition in the small molecule field with a focus on neurotoxicology and efforts being made to improve success via the development of imaging and fluidic biomarkers. We also look at learnings from other models of CNS damage and degeneration such as Parkinson’s disease, traumatic brain injury, and multiple sclerosis since these may offer the opportunity to improve tools available to nonclinical toxicologists in the early detection of potential neurotoxicity. Reciprocally, learnings from studies of animal neurotoxicity may offer better ways to potentially monitor patients during clinical development of new drugs for neurodegeneration. Impact statement Attrition in drug discovery and development remains a major challenge. Safety/toxicity is the most prevalent reason for failure with cardiovascular and CNS toxicities predominating. Non-invasive biomarkers of neurotoxicity would provide significant advantage by allowing earlier prediction of likely neurotoxicity in preclinical studies as well as facilitating clinical trials of new therapies for neurodegenerative conditions such as Parkinson’s disease (PD) and multiple sclerosis (MS).

scholarly journals Visible-Light, Iodine-Promoted Formation of N-Sulfonyl Imines and N-Alkylsulfonamides from Aldehydes and Hypervalent Iodine Reagents

Molecules ◽  
2018 ◽  
Vol 23 (8) ◽  
pp. 1838 ◽  
Author(s):  
Megan Hopkins ◽  
Zachary Brandeburg ◽  
Andrew Hanson ◽  
Angus Lamar
Keyword(s):  
Drug Discovery ◽  
Visible Light ◽  
Initial Step ◽  
Hypervalent Iodine ◽  
Mechanistic Studies ◽  
Synthetic Methodology ◽  
Reaction Conditions ◽  
Drug Discovery And Development ◽  
Radical Initiator ◽  
Reaction Proceeds

Alternative synthetic methodology for the direct installation of sulfonamide functionality is a highly desirable goal within the domain of drug discovery and development. The formation of synthetically valuable N-sulfonyl imines from a range of aldehydes, sulfonamides, and PhI(OAc)2 under practical and mild reaction conditions has been developed. According to mechanistic studies described within, the reaction proceeds through an initial step involving a radical initiator (generated either by visible-light or heat) to activate the reacting substrates. The reaction provides a synthetically useful and operationally simple, relatively mild alternative to the traditional formation of N-sulfonyl imines that utilizes stable, widely available reagents.

Sitagliptin: a potential drug for the treatment of SARS-CoV-2?

2020 ◽  
Author(s):  
Sanaa Bardaweel
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Antimalarial Drug ◽  
Drug Repurposing ◽  
Spike Protein ◽  
Diabetic Patients ◽  
Potential Drug ◽  
Chemokine Production ◽  
Drug Discovery And Development ◽  
Sequence Identity

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.

The State of the Art in Anti-Malarial Drug Discovery and Development

2011 ◽  
Vol 999 (999) ◽  
pp. 1-29
Author(s):  
Jeremy N. Burrows ◽  
Kelly Chibale ◽  
Timothy N.C. Wells
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
The State ◽  
Drug Discovery And Development
Sign in / Sign up

Export Citation Format

Share Document